Evaluation of DNA Repair Function as a Predictor of Response in a Clinical Trial of PARP Inhibitor Monotherapy for Recurrent Ovarian Carcinoma
Technical Report,30 Sep 2014,29 Sep 2015
Mayo Clinic Rochester United States
Pagination or Media Count:
This document provides an annual progress report for the grant W81XWH-13-1-0485 entitled Ovarian Cancer Biomarkers That Predict Response to PARP Inhibitors and Platinum. Over the past 12 months we have i completed validation of the immunohistochemical assays for components of the NHEJ pathway, ii successfully transferred these assays to the Mayo Clinic Pathology Research Core laboratory, which optimized them for performance on an autostainer and iii continued acquisition of tissue specimens from the initially proposed 180-patient phase 2 rucaparib trial ARIEL2, part 1 ClinicalTrials.gov identifier NCT01891344, which will be subjected to IHC staining and scoring as one batch per the deliberations of the statisticians associated with this grant and the ARIEL2 trial. A more complete abstract is provided on page 4 of this document.